Beta Bionics, Inc./$BBNX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Beta Bionics, Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.
- Ticker
- $BBNX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 422
- Headquarters
- Irvine, United States
- Website
- www.betabionics.com
BBNX Metrics
BasicAdvanced
$911M
-
-$1.85
-
-
Price and volume
Market cap
$911M
52-week high
$32.71
52-week low
$8.80
Average daily volume
1.1M
Financial strength
Current ratio
8.921
Quick ratio
8.038
Long term debt to equity
0.012
Total debt to equity
0.015
Profitability
EBITDA (TTM)
-89.858
Gross margin (TTM)
58.63%
Net profit margin (TTM)
-65.31%
Operating margin (TTM)
-72.75%
Revenue per employee (TTM)
$300,000
Management effectiveness
Return on assets (TTM)
-14.96%
Return on equity (TTM)
-23.88%
Valuation
Price to revenue (TTM)
5.92
Price to book
2.27
Price to tangible book (TTM)
2.27
Price to free cash flow (TTM)
-11.421
Free cash flow yield (TTM)
-8.76%
Free cash flow per share (TTM)
-1.467
Growth
Revenue change (TTM)
43.69%
Earnings per share change (TTM)
-26.08%
What the Analysts think about BBNX
Analyst ratings (Buy, Hold, Sell) for Beta Bionics, Inc. stock.
Analyst projections of the future price of Beta Bionics, Inc. stock.
Bulls say / Bears say
Third-quarter sales rose 30% year on year to $35.5 million, while pharmacy-benefit sales more than doubled. This points to a growing recurring-sales channel and greater access for patients. (Beta Bionics)
The FDA has cleared Mint, Beta Bionics’ patch pump, with a full US launch planned for the first quarter of 2027. The company expects capacity for at least 1.5 million disposable units in 2027, giving it a second product to build on its existing business. (Beta Bionics)
The company completed enrolment in its US pivotal trial of iLet for adults with type 2 diabetes and expects to seek an expanded indication around mid-2027, subject to FDA clearance. Success could open a larger patient market beyond its current type 1 diabetes focus. (Beta Bionics)
Operating losses widened as spending grew faster than sales: the third-quarter operating loss rose to $26.6 million from $17.0 million a year earlier. Adjusted EBITDA also deteriorated, leaving the business reliant on future growth to improve its economics. (Beta Bionics)
Management says prospective users may wait for Mint, creating a potential revenue deferral of up to $8.5 million in the fourth quarter. That makes the near-term sales outlook vulnerable to launch timing and customer hesitation. (Beta Bionics)
The company withdrew its 510(k) submission for the next-generation 3D Intelligence algorithm after FDA discussions and says it needs to provide additional validation data. A revised submission is planned, but clearance and launch timing remain uncertain. (Beta Bionics)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.
BBNX Financial Performance
Revenues and expenses
BBNX Earnings Performance
Company profitability
Upcoming events
No upcoming events
BBNX News
AllArticlesVideos
BBNX FINAL DEADLINE: ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Beta Bionics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important November 3 Deadline in Securities Class Action - BBNX
Newsfile Corp12 hours ago
Beta Bionics 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Beta Bionics, Inc. - BBNX
Business Wire2 days ago
BBNX FINAL DEADLINE: ROSEN, REGARDED INVESTOR RIGHTS COUNSEL, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important November 3 Deadline in Securities Class Action - BBNX
Newsfile Corp2 days ago
Funds containing BBNX
Fund name | Fund size | $BBNX weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.03% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.